The investment will support development of radioligand therapies for cancer based on lead-212 alpha-emitting isotopes.

GE HealthCare will equip a new Theranostics Center of Excellence in Germany with advanced PET/CT imaging and artificial intelligence technologies.

The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.

Patients with EGFR- and MET-altered NSCLC benefitted from treatment with the drug combo after progressing on Tagrisso alone.

The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.

The drugmaker met increased demand following approval of Carvykti in earlier lines of therapy with expanded production at US and European facilities.

The partners will incorporate BostonGene's Tumor Portrait tests into SCRI's Phase I clinical trials to explore the use of HLA typing for pre-screening patients.

The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.

The researchers previously received a single-patient approval to administer a second dose of the treatment in the study.

Investigators will evaluate the safety, tolerability, and exploratory signs of efficacy, including neurofilament light chain and SOD1 protein.

Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.

With A$45 million in funding, the group will focus on research developing safer therapies and clinical trial programs for pediatric cancer treatment.